Development of prohibitin ligands against osteoporosis

Current therapeutic approaches to osteoporosis display some potential adverse effects and a limited efficacy on non-vertebral fracture reduction. Some sulfonylamidines targeting the scaffold proteins prohibitins-1 2 (PHB1/2) have been showed inhibit formation of osteoclasts in charge bone resorption. Herein, we report development second generation anti-osteoclastic PHB ligands. The most potent compound, IN45, 88% inhibition at low concentration 5 ?M, indicates that it might serve as basis for new antiosteoporotic drugs.